Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges.
暂无分享,去创建一个
P. Massion | P. Mazzone | A. Spira | M. Boeri | G. Sozzi | L. Montuenga | R. Pio | J. Field | N. Peled | J. Zulueta | L. Seijo | D. Ajona
[1] Ruijiang Li,et al. A Quantitative CT Imaging Signature Predicts Survival and Complements Established Prognosticators in Stage I Non-Small Cell Lung Cancer. , 2018, International journal of radiation oncology, biology, physics.
[2] S. Hanash,et al. Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins , 2018, JAMA oncology.
[3] L. Wain,et al. Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk , 2018, Nature Communications.
[4] B. Hennessy,et al. Brief Report on the Detection of the EGFR T790M Mutation in Exhaled Breath Condensate from Lung Cancer Patients , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[5] I. Wistuba,et al. A novel protein‐based prognostic signature improves risk stratification to guide clinical management in early‐stage lung adenocarcinoma patients , 2018, The Journal of pathology.
[6] S. Plevritis,et al. Genome-wide sequencing for early stage lung cancer detection from plasma cell-free DNA (cfDNA): The Circulating Cancer Genome Atlas (CCGA) study. , 2018, Journal of Clinical Oncology.
[7] D. Wood. POINT: Should Lung Cancer Screening Be Expanded to Persons Who Don't Currently Meet Accepted Criteria Set Forth by the CHEST Guidelines on Lung Cancer Screening? Yes. , 2018, Chest.
[8] J. Jett,et al. Cost-effectiveness of an autoantibody test (EarlyCDT-Lung) as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules , 2018, PloS one.
[9] J. Benítez,et al. Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco‐induced lung cancer , 2018, Cancer medicine.
[10] K. Brothers,et al. Tensions in ethics and policy created by National Precision Medicine Programs , 2018, Human Genomics.
[11] P. Mazzone,et al. Screening for Lung Cancer: CHEST Guideline and Expert Panel Report , 2018, Chest.
[12] Maximilian Diehn,et al. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. , 2018, Archives of pathology & laboratory medicine.
[13] Brooke L. Billman,et al. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Paul Kearney,et al. Assessment of Plasma Proteomics Biomarker’s Ability to Distinguish Benign From Malignant Lung Nodules , 2018, Chest.
[15] Ludmila V. Danilova,et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test , 2018, Science.
[16] M. Lenburg,et al. The Airway Transcriptome as a Biomarker for Early Lung Cancer Detection , 2018, Clinical Cancer Research.
[17] P. Mazzone,et al. Evaluation of a Serum Lung Cancer Biomarker Panel , 2018, Biomarker insights.
[18] Daniel R. Schrider,et al. Supervised Machine Learning for Population Genetics: A New Paradigm , 2018, Trends in genetics : TIG.
[19] H. Blons,et al. Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer , 2018, Oncoimmunology.
[20] P. Massion,et al. Complement C4d-specific antibodies for the diagnosis of lung cancer , 2017, Oncotarget.
[21] Witold Rzyman,et al. European position statement on lung cancer screening. , 2017, The Lancet. Oncology.
[22] Kefeng Li,et al. Next-generation metabolomics in lung cancer diagnosis, treatment and precision medicine: mini review , 2017, Oncotarget.
[23] Bram van Ginneken,et al. Malignancy risk estimation of pulmonary nodules in screening CTs: Comparison between a computer model and human observers , 2017, PloS one.
[24] S. Lam,et al. Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study. , 2017, The Lancet. Oncology.
[25] Lin Wang,et al. DNA Methylation Analysis of the SHOX2 and RASSF1A Panel in Bronchoalveolar Lavage Fluid for Lung Cancer Diagnosis , 2017, Journal of Cancer.
[26] Charles A Powell,et al. Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement , 2017, American journal of respiratory and critical care medicine.
[27] Wei-min Li,et al. Development and clinical application of radiomics in lung cancer , 2017, Radiation oncology.
[28] Yun Zhou,et al. A classifier integrating plasma biomarkers and radiological characteristics for distinguishing malignant from benign pulmonary nodules , 2017, International journal of cancer.
[29] Guopeng Zhang,et al. Combining PET/CT with serum tumor markers to improve the evaluation of histological type of suspicious lung cancers , 2017, PloS one.
[30] N. Tanner,et al. Assessing the Generalizability of the National Lung Screening Trial: Comparison of Patients with Stage 1 Disease , 2017, American journal of respiratory and critical care medicine.
[31] Edward S. Kim,et al. Prognostic and predictive biomarkers post curative intent therapy. , 2017, Annals of translational medicine.
[32] H. Pass,et al. A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non–Small Cell Lung Cancer and Serum DNA , 2017, Clinical Cancer Research.
[33] T. Cai,et al. Genetic predisposition to lung cancer: comprehensive literature integration, meta-analysis, and multiple evidence assessment of candidate-gene association studies , 2017, Scientific Reports.
[34] Sam Angiuoli,et al. Direct detection of early-stage cancers using circulating tumor DNA , 2017, Science Translational Medicine.
[35] P. Lambin,et al. Defining the biological basis of radiomic phenotypes in lung cancer , 2017, eLife.
[36] John Quackenbush,et al. Somatic Mutations Drive Distinct Imaging Phenotypes in Lung Cancer. , 2017, Cancer research.
[37] P. Jänne,et al. Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[38] Aegis Study Team. Shared Gene Expression Alterations in Nasal and Bronchial Epithelium for Lung Cancer Detection. , 2017 .
[39] Zhijun Liu,et al. The Combination of the Tumor Markers Suggests the Histological Diagnosis of Lung Cancer , 2017, BioMed research international.
[40] William S. Bush,et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes , 2017, Nature Genetics.
[41] Ashwini Naik,et al. Phylogenetic ctDNA analysis depicts early stage lung cancer evolution , 2017, Nature.
[42] Harry J de Koning,et al. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study , 2017, PLoS medicine.
[43] U. Pastorino,et al. Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening-Detected Lung Cancers , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[44] F. Mair,et al. Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): study protocol for a randomized controlled trial , 2017, BMC Cancer.
[45] J. Robertson,et al. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule‐Based Risk Models for Detection of Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[46] Mark Lee,et al. Next-Generation Sequencing of Circulating Tumor DNA for Early Cancer Detection , 2017, Cell.
[47] R. Tetzner,et al. Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[48] H. Haick,et al. Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules , 2016, ACS nano.
[49] J. Chun,et al. Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions. , 2016, Lung cancer.
[50] Gilles Blanchard,et al. Combining Multiple Hypothesis Testing with Machine Learning Increases the Statistical Power of Genome-wide Association Studies , 2016, Scientific Reports.
[51] F. Jiang,et al. A Prediction Model Based on Biomarkers and Clinical Characteristics for Detection of Lung Cancer in Pulmonary Nodules12 , 2016, Translational oncology.
[52] J. Herman,et al. Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum , 2016, Clinical Cancer Research.
[53] Dennis J. Hazelett,et al. The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers , 2016, Cancer Epidemiology, Biomarkers & Prevention.
[54] Hans J Lee,et al. The Percepta Registry: A Prospective Registry to Evaluate Percepta Bronchial Genomic Classifier Patient Data , 2016 .
[55] P. Massion,et al. The Pursuit of Noninvasive Diagnosis of Lung Cancer , 2016, Seminars in Respiratory and Critical Care Medicine.
[56] Yang Liu,et al. Circulating tumor DNA detection in lung cancer patients before and after surgery , 2016, Scientific Reports.
[57] Y. Liu,et al. Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas. , 2016, Clinical lung cancer.
[58] Jieun Park,et al. Characterization of microbiome in patients with lung cancer comparing with benign mass-like lesions , 2016 .
[59] G. Silvestri,et al. Clinical Utility of a Bronchial Genomic Classifier in Patients With Suspected Lung Cancer. , 2016, Chest.
[60] P. V. van Ooijen,et al. Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval , 2016, Thorax.
[61] M. Broggini,et al. Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS , 2016, Oncotarget.
[62] Hossam Haick,et al. Exhaled Breath Analysis for Monitoring Response to Treatment in Advanced Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[63] John K Field,et al. The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. , 2016, Health technology assessment.
[64] V. Backman,et al. Procedures for risk-stratification of lung cancer using buccal nanocytology. , 2016, Biomedical optics express.
[65] Oliver Fiehn,et al. Serum phosphatidylethanolamine levels distinguish benign from malignant solitary pulmonary nodules and represent a potential diagnostic biomarker for lung cancer. , 2016, Cancer biomarkers : section A of Disease markers.
[66] M. Beckmann,et al. The metabolomic detection of lung cancer biomarkers in sputum. , 2016, Lung cancer.
[67] William J Blot,et al. Urinary Metabolite Risk Biomarkers of Lung Cancer: A Prospective Cohort Study , 2016, Cancer Epidemiology, Biomarkers & Prevention.
[68] F. Priego-Capote,et al. Identification of metabolomics panels for potential lung cancer screening by analysis of exhaled breath condensate , 2016, Journal of breath research.
[69] Bram van Ginneken,et al. Pulmonary Nodule Detection in CT Images: False Positive Reduction Using Multi-View Convolutional Networks , 2016, IEEE Transactions on Medical Imaging.
[70] G. Kennedy,et al. Analytical performance of a bronchial genomic classifier , 2016, BMC Cancer.
[71] J. Dopazo,et al. Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer , 2016, Oncotarget.
[72] A. Agustí,et al. Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer. , 2016, American journal of respiratory and critical care medicine.
[73] C. la Vecchia,et al. Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening , 2015, Oncotarget.
[74] Christy A. Lancaster,et al. The Cell‐CT 3‐dimensional cell imaging technology platform enables the detection of lung cancer using the noninvasive LuCED sputum test , 2015, Cancer cytopathology.
[75] M. Lemieux,et al. Early Detection of Lung Cancer with Meso Tetra (4-Carboxyphenyl) Porphyrin-Labeled Sputum , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[76] N. Peled,et al. Screening for Lung Cancer: What Comes Next? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] Oliver Fiehn,et al. Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non-Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] G. Silvestri,et al. A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer. , 2015, The New England journal of medicine.
[79] M. Wielscher,et al. Diagnostic Performance of Plasma DNA Methylation Profiles in Lung Cancer, Pulmonary Fibrosis and COPD , 2015, EBioMedicine.
[80] Wei Shen,et al. Multi-scale Convolutional Neural Networks for Lung Nodule Classification , 2015, IPMI.
[81] Massimo Bellomi,et al. miR-Test: a blood test for lung cancer early detection. , 2015, Journal of the National Cancer Institute.
[82] U. Pastorino,et al. Recent advances of microRNA-based molecular diagnostics to reduce false-positive lung cancer imaging , 2015, Expert review of molecular diagnostics.
[83] J. Jett,et al. Progress in the development of volatile exhaled breath signatures of lung cancer. , 2015, Annals of the American Thoracic Society.
[84] Avrum Spira,et al. Derivation of a bronchial genomic classifier for lung cancer in a prospective study of patients undergoing diagnostic bronchoscopy , 2015, BMC Medical Genomics.
[85] J. Weissfeld,et al. Improving selection criteria for lung cancer screening. The potential role of emphysema. , 2015, American journal of respiratory and critical care medicine.
[86] V. Doseeva,et al. Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer , 2015, Journal of Translational Medicine.
[87] G. Apolone,et al. Smoking Cessation Intervention Within the Framework of a Lung Cancer Screening Program: Preliminary Results and Clinical Perspectives from the “Cosmos-II” Trial , 2015, Lung.
[88] B. Celli,et al. Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. , 2015, American journal of respiratory and critical care medicine.
[89] Jian Su,et al. Sputum microRNA Biomarkers for Identifying Lung Cancer in Indeterminate Solitary Pulmonary Nodules , 2015, Clinical Cancer Research.
[90] Dong Liang,et al. The Ability of Bilirubin in Identifying Smokers with Higher Risk of Lung Cancer: A Large Cohort Study in Conjunction with Global Metabolomic Profiling , 2014, Clinical Cancer Research.
[91] W. Rom. Biomarkers for lung cancer. , 2014, Respiratory investigation.
[92] Francisco J. Planes,et al. In-Silico Prediction of Key Metabolic Differences between Two Non-Small Cell Lung Cancer Subtypes , 2014, PloS one.
[93] Emmanuel Hatzakis,et al. Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer. , 2014, Cancer research.
[94] Christy A. Lancaster,et al. Early detection of lung cancer based on three-dimensional, morphometric analysis of cells from sputum. , 2014 .
[95] S. de Lusignan,et al. Genetic test to stop smoking (GeTSS) trial protocol: randomised controlled trial of a genetic test (Respiragene) and Auckland formula to assess lung cancer risk , 2014, BMC Pulmonary Medicine.
[96] C. la Vecchia,et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[97] V. Moyer. Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2014, Annals of Internal Medicine.
[98] Ash A. Alizadeh,et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage , 2013, Nature Medicine.
[99] Heidi Roberts,et al. Screening High-Risk Populations for Lung Cancer: Guideline Recommendations , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[100] S. Lam,et al. Signal stratification of autoantibody levels in serum samples and its application to the early detection of lung cancer. , 2013, Journal of thoracic disease.
[101] P. Massion,et al. Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer. , 2013, Journal of the National Cancer Institute.
[102] Radu Ionescu,et al. Volatile fingerprints of cancer specific genetic mutations. , 2013, Nanomedicine : nanotechnology, biology, and medicine.
[103] Timothy R Church,et al. Selection criteria for lung-cancer screening. , 2013, The New England journal of medicine.
[104] J. Robertson,et al. Application of a High Throughput Method of Biomarker Discovery to Improvement of the EarlyCDT®-Lung Test , 2012, PloS one.
[105] H. Haick,et al. Non-invasive Breath Analysis of Pulmonary Nodules , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[106] Hossam Haick,et al. Volatile organic compounds of lung cancer and possible biochemical pathways. , 2012, Chemical reviews.
[107] C. Berg,et al. Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered? , 2012, Journal of medical screening.
[108] P. Boyle,et al. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays , 2012, Tumor Biology.
[109] Patrick Granton,et al. Radiomics: extracting more information from medical images using advanced feature analysis. , 2012, European journal of cancer.
[110] J. Jett,et al. Added Value of a Serum Proteomic Signature in the Diagnostic Evaluation of Lung Nodules , 2012, Cancer Epidemiology, Biomarkers & Prevention.
[111] C. Gatsonis,et al. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .
[112] Massimo Bellomi,et al. Lung Cancer Risk Prediction to Select Smokers for Screening CT—a Model Based on the Italian COSMOS Trial , 2011, Cancer Prevention Research.
[113] Patrick Maisonneuve,et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer , 2011, EMBO molecular medicine.
[114] P. Prorok,et al. Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation. , 2011, Journal of the National Cancer Institute.
[115] S. Lam,et al. EarlyCDT-Lung: An Immunobiomarker Test as an Aid to Early Detection of Lung Cancer , 2011, Cancer Prevention Research.
[116] Ugo Pastorino,et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer , 2011, Proceedings of the National Academy of Sciences.
[117] P. Boyle,et al. Clinical validation of an autoantibody test for lung cancer , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[118] H. Haick,et al. Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors , 2010, British Journal of Cancer.
[119] Christopher R Kinsinger,et al. Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics. , 2010, Clinical chemistry.
[120] Malik Yousef,et al. Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease. , 2009, Cancer research.
[121] M. Ehrlich. DNA hypomethylation in cancer cells. , 2009, Epigenomics.
[122] Thomas M. Blomquist,et al. Pattern of antioxidant and DNA repair gene expression in normal airway epithelium associated with lung cancer diagnosis. , 2009, Cancer research.
[123] Zhenqiu Liu,et al. Combined genetic analysis of sputum and computed tomography for noninvasive diagnosis of non-small-cell lung cancer. , 2009, Lung cancer.
[124] S. Duffy,et al. The LLP risk model: an individual risk prediction model for lung cancer , 2007, British Journal of Cancer.
[125] P. Sebastiani,et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer , 2007, Nature Medicine.
[126] J. Jett,et al. A comparison of cytology and fluorescence in situ hybridization for the detection of lung cancer in bronchoscopic specimens. , 2006, Chest.
[127] R. Stephens,et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.
[128] M S Pepe,et al. Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.
[129] D. DeMets,et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.
[130] R. Dziadziuszko,et al. Panel of serum metabolites discriminates cancer patients and healthy participants of lung cancer screening - a pilot study. , 2017, Acta biochimica Polonica.
[131] Joseph F. Perez-Rogers,et al. Shared Gene Expression Alterations in Nasal and Bronchial Epithelium for Lung Cancer Detection , 2017, Journal of the National Cancer Institute.
[132] J. Jett,et al. udit of the autoantibody test , EarlyCDT ®-Lung , in 1600 patients : n evaluation of its performance in routine clinical practice , 2014 .
[133] William E Grizzle,et al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. , 2009, Journal of proteome research.
[134] O. Miettinen,et al. CT screening for lung cancer: significance of diagnoses in its baseline cycle. , 2006, Clinical imaging.
[135] G. Byrnes,et al. Screening for lung cancer. , 2004, The Cochrane database of systematic reviews.
[136] J. Herman,et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. , 1999, Cancer research.